0000000000261272

AUTHOR

Nicole Jaeger

showing 2 related works from this author

Effect of Rivaroxaban and Aspirin in Patients With Peripheral Artery Disease Undergoing Surgical Revascularization: Insights From the VOYAGER PAD Tri…

2021

Background: Patients with peripheral artery disease requiring lower extremity revascularization (LER) are at high risk of adverse limb and cardiovascular events. The VOYAGER PAD trial (Vascular Outcomes Study of ASA [Acetylsalicylic Acid] Along With Rivaroxaban in Endovascular or Surgical Limb Revascularization for PAD) demonstrated that rivaroxaban significantly reduced this risk. The efficacy and safety of rivaroxaban has not been described in patients who underwent surgical LER. Methods: The VOYAGER PAD trial randomized patients with peripheral artery disease after surgical and endovascular LER to rivaroxaban 2.5 mg twice daily plus aspirin or matching placebo plus aspirin and followed …

Lower extremity revascularizationMalemedicine.medical_specialtylower extremity revascularization; major adverse cardiovascular events (MACE); major adverse limb events (MALE); peripheral artery disease; revascularization; rivaroxaban.lower extremity revascularizationArterial diseasemedicine.medical_treatmentDiseaseRevascularizationperipheral artery diseasePeripheral Arterial DiseaseRivaroxabanPhysiology (medical)Internal medicinemedicineHumansIn patientmajor adverse cardiovascular events (MACE)major adverse limb events (MALE)AgedRivaroxabanAspirinAspirinbusiness.industryMiddle AgedCardiologyrevascularizationFemaleCardiology and Cardiovascular Medicinebusinessmedicine.drugSurgical revascularizationCirculation
researchProduct

Rivaroxaban in Peripheral Artery Disease after Revascularization

2020

Abstract Background Patients with peripheral artery disease who have undergone lower-extremity revascularization are at high risk for major adverse limb and cardiovascular events. The efficacy and ...

RivaroxabanAspirinmedicine.medical_specialtyArterial diseasebusiness.industrymedicine.medical_treatmentGeneral MedicineDisease030204 cardiovascular system & hematologyRevascularizationlaw.invention03 medical and health sciences0302 clinical medicinePharmacotherapyRandomized controlled trialMulticenter studylawInternal medicineCardiologyMedicine030212 general & internal medicinebusinessmedicine.drugNew England Journal of Medicine
researchProduct